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The sacred lotus Eclipta prostrata or commonly known as 
“false daisy”, has long been used in traditional Chinese 
medicine for a diverse range of ailments, from treating 
alopecia to liver enlargement or asthma (1). E. prostrata 
contains a multitude of chemical compounds including 
triterpenoids, steroids, flavonoids, coumestans, saponins 
and other volati le oils  (2) .  According to Chinese 
Pharmacopoeia, the primary effect of the dried aerial part of 
E. prostrata can “cool” the blood and serves as a coagulating 
agent (3). Another reported therapeutic attribute is the 
anticancer properties of E. prostrata extracts (4,5). However, 
the identification of the key components responsible 
for this antitumoral activity and mechanism of action 
remain unclear. A new study from Annals of Translational 
Medicine now reports that one of the extracted compounds, 
Ecliptasaponin A (ES), has anticancer effects on non-small 
cell lung cancer (NSCLC) (6).
The pentacyclic triterpenoid ES is structurally identical 
to Eclalbasaponin II (E-II) (1). E-II has previously shown to 
exhibit antiproliferative effects in hepatic stellate cells (7). 
In human ovarian cancer cells, E-II induces autophagic and 
apoptotic cell death through the regulation of JNK, p38 
and mTOR signaling (8). The recently published study in 
Annals of Translational Medicine suggests that ES can be a 
promising therapeutic agent in lung cancer (6). Through 
a series of canonical experiments, Han et al. demonstrated 
a potent inhibition in lung cancer cells viability after 
ES treatment. The paper dug deep into the molecular 
mechanisms to further elucidate ES-mediated activation of 
apoptosis and autophagy, driving cell death. 
For their studies, the authors used H460 and H1975 
NSCLC cell lines. NSCLC accounts for ~85% of all 
cases of lung cancer including adenocarcinoma, large-cell 
carcinoma and squamous-cell carcinoma (9). ES inhibited 
cell growth of both cell lines in a dose- and time-dependent 
manner. ES treated cells also exhibited impaired ability to 
form colonies in soft agar. To test the cancer killing effect 
of ES in vivo, H640 cells were implanted subcutaneously 
in nude mice. Consistent with the in vitro results, ES 
treatment resulted in reduced tumor burden and tumor 
weight. Importantly, ES did not affect mice body weight, 
suggesting the compound is overall well tolerated.  
With these data in hand, the authors proceed to 
identify and characterize the modality of death that lung 
cancer cells underwent after being treated with ES. Most 
anticancer drugs currently used in clinical oncology exploit 
the apoptotic signaling pathways to trigger cancer cell 
death (10). Consistent with this, Han et al. observed the 
hallmark signs of apoptosis including cell shrinkage, 
condensed nuclei, and an overall cell number reduction 
post-treatment. Treatment with ES elicited both the 
intrinsic and extrinsic apoptotic pathways as evidenced 
by cleavage of caspase-3, -8 and -9. Fluorescent-based 
visualization of microtubule-associated protein 1 light chain 
3 (LC3) also revealed the existence of autophagic activity. 
Autophagy manifested with the formation of vesicles 
(autophagosomes) that engulf cellular macromolecules and 
organelles and culminates with lysosomal degradation (11). 
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ES treatment also altered the expression of other 
autophagy-related proteins such as Beclin-1 and P62/
SQSTM1 in both cell lines. 
Regulated modes of cell death such as autophagy can act 
in concert with apoptotic signaling to induce cell death (11). 
However, autophagy activation preceding cell death does 
not suggest causality; autophagy can also be a rescue 
mechanism to escape apoptosis (12,13). That being said, 
does the ES-mediated autophagy contribute to apoptosis 
in NSCLC cells or is it just a salvage pathway? Han 
et al. addressed this question by conducting combinatorial 
treatments of ES with classic autophagy inhibitors: 
3-methyladenine (3-MA) or chloroquine (CQ). These 
drugs inhibit autophagy at different stages: 3-MA 
blocks autophagy at early phases whilst CQ affects late 
autophagy (14). Treatment with either inhibitors with ES 
resulted in a reduction of apoptotic events, confirming that 
autophagy contributes to ES-induced cell death in NSCLC 
cells.
Finally, to identify potential signaling pathways involved 
in ES-induced apoptosis and autophagy, the authors 
analyze several phospho-kinases belonging or related to 
the mitogen-activated protein kinase (MAPK) pathway. 
Apoptosis signal-regulating kinase 1 (ASK1) is a member 
of the MAPK kinase kinase kinase (MAP3K) family that 
activates downstream MAPKs, c-Jun N-terminal kinases 
(JNKs) and p38, and plays a key role in various stress 
responses, including cell death (15). The authors found 
that ES treatment induced ASK1, JNK, AKT and p38 
phosphorylation whereas p-ERK levels were reduced. They 
also investigated the JNK signaling pathway as previous 
literature shows its involvement in regulating multiple 
modalities of cell death (16). Combinatorial treatment of 
ES with specific AKS1 and JNK1 inhibitors (GS-4997 and 
SP600125, respectively) reduced the number of apoptotic 
events and expression of cleaved caspase-3 compared to 
ES-treatment alone. The JNK1 inhibitor also prevented 
ES-induced autophagic activity as shown by LC3 levels. 
Taken together, these results demonstrate that ES induces 
apoptosis and autophagy through activation of the JNK 
pathway. 
Conclusions and perspectives
Lung cancer is the leading cause of cancer-related 
deaths among men and women. In 2017, lung cancer 
caused more deaths than breast, prostate, colorectal, 
and brain cancers combined (17). Despite significant 
progress in the oncological management of lung cancer 
in recent years, the clinical outcomes are still not at a 
satisfactory level and the need for better therapeutic 
regimens is clear. This study provides a new strategy 
for lung cancer treatment that involves the use of the 
phytochemical Ecliptasaponin A. Phytochemicals and 
derivatives have been widely used in chemotherapy 
of cancer patients (e.g., taxol analogs, vinca alkaloids, 
podophyllotoxin analogues) (18) and several of these 
compounds are being actively evaluated for use as adjuvants 
in anticancer therapies (e.g., immunomodulation) (19). 
The study by Han et al. opens the door to the evaluation of 
other anticancer activities ES may have, that could easily 
expand its cytotoxic effect on cancer cells. Combination 
therapy involving ES with standard of care chemotherapy 
drugs should be tested, as ES treatment might sensitize 
NSCLC cells to other therapy and/or help to overcome 
drug resistance. The use of omics approaches in future 
studies will help to get a better insight and accelerate the 
understanding on ES potential pleiotropy, molecular targets 
and hierarchical mechanisms. 
Low lung cancer survival rates reflect the large 
proportion of patients (57%) diagnosed with metastatic 
disease (5-year survival for stage IV is 5%) (20). E. prostrata 
extracts have shown to attenuate migration and invasion 
of a variety of cancer cell lines and endothelial cells 
(21,22). Futures studies will need to address whether ES 
plays any role in cancer metastasis and explore its role in 
advanced lung cancer. This compound also provides a new 
opportunity in chemoprevention research. ES has been 
reported to exert preventive effects in bleomycin-induced 
pulmonary fibrosis in mice (23). E. prostrata components 
also showed to exhibit protective properties in human 
bronchial epithelial cells in which oxidative stress injury and 
inflammation responses are induced by continuous cigarette 
smoke exposure (24). These data suggest that efforts should 
be directed towards investigating the role of ES as an agent 
with the potential of preventing disease development and 
progression. ES is extracted from what farmers consider 
a weed and its use in Asian traditional medicine can be 
tracked back to 3,000 year ago. Modern medicine could 
now benefit from a weed that grows at our fingertips. Let’s 
teach an old drug new tricks and use it to our advantage.
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